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ABSTRACT
The majority of unrelated donor (UD) hematopoietic stem cell (HSC) transplants are performed across
HLA-DP mismatches, which, if involving disparity in a host-versus-graft (HVG) direction for an alloreactive
T cell epitope (TCE), have been shown by our group to be associated with poor clinical outcome in 2 cohorts
of patients transplanted for hematopoietic malignancies and beta-thalassemia, respectively. Using site-directed
mutagenesis of DPB1*0901, we show here that the TCE is abrogated by the presence of amino acids LFQG
in positions 8-11 of the DP beta-chain. Based on this and on alloreactive T cell responsiveness, we have
determined the presence or absence of the TCE for 72 DPB1 alleles reported in the ethnic groups represen-
tative of the worldwide UD registries, and predict that 67%-87% (mean 77%) of UD recipient pairs will not
present a DPB1 TCE disparity in the HVG direction. We developed and validated in 112 healthy Italian blood
donors an innovative approach of DPB1 epitope-specific typing (EST), based on 2 PCR reactions. Our data
show that DPB1 TCE disparities may hamper the clinical success of a considerable number of transplants when
DPB1 matching is not included into the donor selection criteria, and that a donor without DPB1 TCE
disparities in the HVG direction can be found for the majority of patients. Moreover, the study describes the
first protocol of targeted epitope-specific DPB1 donor-recipient matching for unrelated HSC transplantation.
This protocol will facilitate large-scale retrospective clinical studies warranted to more precisely determine the
clinical relevance of DPB1 TCE disparities in different transplant conditions.
© 2007 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell (HSC) transplantation
rom matched unrelated donors (UDs) is increasingly
eing used both in the United States (CIBMTR, Cen-
er for International Blood and Marrow Transplants
esearch; http://www.ibmtr.org ) and in Europe [1]
or the cure of a variety of neoplastic or genetic dis-
ases of the hematopoietic system, including leuke-
ia, lymphoma, multiple myeloma, or severe com- wined immunodeﬁciency (SCID) and beta-thalassemia
2,3]. The clinical success of unrelated HSC trans-
lantation is critically dependent on the degree of
D-recipient matching for the human leukocyte an-
igen (HLA) class I and II antigens (Ags) encoded
ithin the major histocompatibility complex (MHC).
espite an increasingly growing number of HLA-
yped volunteers enrolled in the world-wide registries,
hich to date exceeds 11 million, the probability of
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E. Zino et al.1032nding a UD minimally matched for low-resolution
LA-A, B, and high-resolution HLA-DRB1 alleles
6/6 alleles) varies from 80% in Whites to 40% in
thnic minorities (NMDP, National Marrow Donor
rogram; http://www.marrow.org) [4]. This probabil-
ty decreases to 40% when trying to identify a UD
atched for the additional loci HLA-C and DQB1
10/10 alleles) [5], and is 20% if identity for HLA-
PB1 is included into the matching criteria (12/12
lleles) [6].
The current recommendations of the American
MDP include high-resolution UD-recipient match-
ng for HLA-A, B, C, and DRB1, whereas disparity
or DQB1 and DPB1 is not considered to be relevant
7-9]. Because of weak linkage disequilibrium between
PB1 and the other HLA class II loci [10-12], over
0% of UD transplants are performed across mis-
atches at DPB1 [6]. On the other hand, numerous
tudies including our own have shown in the past that
he degree of DPB1 matching can have an impact on
he outcome of HSC transplantation from UDs
6,13-18]. In particular, we and others have shown
hat HLA-DP Ags can be targets of acute immune-
ediated HSC allograft rejection [19] and acute graft-
ersus-host-disease (aGVHD) [20,21]. On the basis of
eactivity by HLA-DP-speciﬁc alloreactive T cells we
ave recently developed an algorithm for UD-recipi-
nt disparities for a shared T cell epitope (TCE)
ncoded by a subset of DPB1 alleles [13]. According
o this algorithm, individuals carrying self-DPB1 al-
eles encoding the TCE will have clonally deleted
lloreactive T cells for the shared epitope, whereas
ndividuals carrying self-DPB1 alleles lacking the
CE will have retained TCE-speciﬁc alloreactive T
ells in their repertoire. Depending on the combina-
ion of DPB1 alleles present in the donor and in the
ecipient of an unrelated stem cell transplantation
SCT), DPB1 disparities can therefore be classiﬁed as
CE permissive (both donor and recipient or none of
he 2 carry at least 1 DPB1 allele encoding the TCE)
r TCE disparate. TCE disparities can be either in the
VG direction (nonpermissive HVG: the donor car-
ies at least 1 DPB1 allele encoding the TCE, whereas
he recipient does not), or in the GVH direction
nonpermissive GVH: the recipient carries at least 1
PB1 allele encoding the TCE whereas the donor does
ot). According to these deﬁnitions, TCE matching sta-
us for a donor-recipient pair is unambiguous, and dis-
arities in HVG and GVH directions are mutually ex-
lusive. In our retrospective clinical studies, DPB1 TCE
isparities were found to be associated with an increased
isk of aGVHD and treatment-related mortality (TRM)
n oncohematologic patients [13] and of graft rejection in
eta-thalassemia patients [22].
In the present study, we have used site-directed
utagenesis to deﬁne the presence or absence of the
PB1 TCE in 72 out of 114 DPB1 alleles reported to fate, and calculated the predicted frequency of DPB1
CE donor-recipient disparities in various ethnic
roups. Moreover, we present an innovative protocol
or rapid, targeted detection of DPB1 TCE disparities
y epitope-speciﬁc typing (EST), which will improve
he feasibility of large-scale retrospective clinical stud-
es needed to better deﬁne the clinical relevance of
PB1 TCE disparities in different transplant settings.
ATERIALS AND METHODS
eferences Cell Lines
Epstein Barr Virus (EBV) transformed B lympho-
lastoid cell lines (BLCL) from the Xth International
istocompatibility Workshop, available through the
uropean Collection of Animal Cell Cultures, were used
s controls for both conventional allele-speciﬁc DPB1 typ-
ng and EST.DPB1 typing of these BLCLs was as follows:
.E.C. (DPB1*0401, *4601), WT100BIS (DPB1*0101),
0301 (DPB1*0501), BEL-8-CC (DPB1*0202, *2001),
T14 (DPB1*0201, *1901), CML (DPB1*1401, *0401),
nd BM21 (DPB1*1001). The following BLCLs were
stablished from peripheral blood mononuclear cells
PBMCs) from donors DPB1 typed in our laboratory:
SR-DAV (patient BLCL from our previous study
13], DPB1*0201, *0401), HSR-NAM (DPB1*0201,
0502), HSR-190 (DPB1*0402, *3401), HSR-FOCS
DPB1*0401, *3501), HSR-MB (DPB1*0901, *1101),
SR-SL (DPB1*0201, *1701), HSR-366 (DPB1*
401, *1401), and HSR-0208 (DPB1*0402, *1501).
ite-Directed Mutagenesis of DPB1*0901
nd Expression of Mutant Molecules
We generated 2 site-directed mutants of
PB1*0901, designated DPB1*09LF and DPB1*09M/
GPM, encoding aa LFQG in positions 8-11 and
/GGPM in positions 76/84-87 of the DP beta-chain,
espectively (Figure 1). DPB1*09M/GGPM is identical
n sequence to the naturally occurring DPB1*8601 (The
merican Society for Histocompatibility and Immuno-
enetics; http://www.ashi-hla.org) [23,24]. The mutants
ere generated starting from 2 retroviral vector
onstructs carrying the full-length DPB1 cDNA,
DPB1*0901SN and LDPB1*4601SN, described
reviously [13]. Two 643-bp fragments containing the
14 3= codons of the DPB1*0901 or DPB1*4601 cod-
ng regions were removed from the respective vectors
y restriction endonucleases cleavage using an internal
= Mlu I site (Figure 1) and a 3= XhoI site in the
ector’s multiple cloning region, and mutually
wapped. Plasmids encoding mutant molecules were
loned and the full-length 777-bp DPB1 coding re-
ion was sequenced on both strands.
Mutant molecules were expressed in the HSR-
AV BLCL by retroviral vector-mediated gene trans-er as described, and transduced cells were puriﬁed by
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Epitope-Specific Matching for HLA-DPB1 1033agnetic bead selection for the cell surface molecule
NGFR [19]. Expression of mutant DPB1 cDNA in
ransduced cells was detected by RT-PCR followed
y PCR-sequence speciﬁc oligonucleotide probing
SSOP) [25].
unctional Studies Using Alloreactive
Lymphocytes
Isolation and maintenance of HLA-DP-speciﬁc
lloreactive T cell clones 501 and 538 have been
escribed in detail previously [13]. The functional
eactivity of these clones was analyzed by interferon 
IFN-) release assays. Brieﬂy, 10,000 T cells were
ultured with 30,000 target BLCL in 96-well plates in
MDM supplemented with 10% human serum. After
4 hours, supernatant was collected and tested for the
resence of IFN- in a classical ELISA assay, per-
ormed according to the manufacturer’s instructions
BD Pharmingen, San Diego, CA).
PB1 Allelic Polymorphism in Italian Caucasians
Allelic DPB1 frequencies were determined in 216
nrelated healthy Italian blood donors after informed
onsent. Donors were referred from the blood transfu-
ion center ofMagenta, Italy. Brieﬂy, genomicDNAwas
xtracted from 3  106 human mononuclear peripheral
lood cells by the Sigma DNA Extraction kit (Sigma-
ldrich, Steinheim, Germany), according to the man-
facturer’s instructions. Comprehensive, intermediate
esolution genomic typing of the DPB1 locus was
erformed either by locally developed PCR-SSOP, as
reviously described [26] or by commercial PCR-se-
uence speciﬁc priming (SSP; Olerup SSP™ DPB1,
iagen, Vienna, Austria) [25,27].
alculation of the Probability for UD-Recipient
PB1 TCE Matching or Disparity in Different
thnic Groups
We have previously shown that DPB1 alleles
igure 1. Construction of site-directed mutants of DPB1*0901. S
eta-chain, including the 6 hypervariable regions A-F [24,28]. The
equence identity with the consensus. A space was introduced betw
xcising the 643 3= nucleotides of DPB1*0901 that were shufﬂed wit
ncode polypeptides identical in sequence to DPB1*0901 except for
/F (DPB1*09M/GGPM) or aa LFQG in positions 8-11 of hyperan be classiﬁed into 1 of 3 epitope groups, accord- ung to whether or not they encode a polypeptide
arrying an alloreactive TCE [13]. In diploid cells
arrying 2 codominantly expressed DPB1 alleles,
here are 6 possible combinations of the 3 DPB1
pitope groups (1/1, 1/2, 1/3, 2/2, 2/3, 3/3). The
redicted frequency of the presence of each of these 6
ombinations in different ethnic groups was calculated
ccording to the Hardy-Weinberg proportions: (x y
z)2  1, where x, y, and z are the frequencies of
PB1 alleles from epitope groups 1, 2, and 3, respec-
ively. The probability of ﬁnding a deﬁned combination
f DPB1 epitope groups in a given UD-recipient pair was
alculated according to the Hardy-Weinberg proportions:
a b c d e f)2  1, where a, b, c, d, e, and f
re the frequency of individuals with the diploid im-
unogenicity group combinations 1/1, 1/2, 1/3, 2/2,
/3, and 3/3, respectively.
ST of DPB1 Alleles
On the basis of the deduced aa sequence alignment
f DPB1 alleles from epitope groups 1, 2, and 3, we
dentiﬁed 4 aa stretches in hypervariable regions A, D,
nd C, E, respectively, which, when located on the
ame polypeptide, identify the presence or absence of
he alloreactive TCE (The American Society for His-
ocompatibility and Immunogenetics; http://www.
shi-hla.org ) [24,28]. Based on these observations, we
sed primers complementary to nucleotides encoding
he relevant hypervariable regions for the design of 2
CE-speciﬁc PCR reactions. The 2 reactions, desig-
ated EST-AD and EST-CE, give rise to amplicons
f 214 and 92 bp, respectively, which are readily de-
ectable by 2% agarose gel electrophoresis (Table 1).
product of slightly superior size (276 bp) obtained
ith primers suitable for generic ampliﬁcation of all
RB alleles [26], was used as an internal control in
oth reactions. PCR conditions, identical for
ST-AD and EST-CE, were as follows: 75 ng of
enomic DNA were ampliﬁed in a ﬁnal reaction vol-
re the 88 aa encoded by nucleotides 101 to 364 of the HLA-DP
ce encoded by DPB1*0101 is shown as consensus; dashes indicate
15 and 16 to indicate the MLU I restriction site that was used for
of DPB1*4601 to generate 2 site-directed mutants. These mutants
ence of aa M/GGPM in position 76/84-87 of hypervariable regions
region A (DPB1*09LF).hown a
sequen
een aa
h those
the presme of 25 L using dNTPs 0.2 mM, primers 0.5 mM,
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E. Zino et al.1034.03 U/mL of Dynazyme polymerase (Finnzymes, Es-
oo, Finland), in the presence of 0.2 mM glycerol.
hermal cycler conditions were: 1 cycle of 4 minutes
t 95°C, 10 cycles of 15 seconds at 95°C, and 10
econds at 56°C, 20 cycles of 15 seconds at 95°C, 10
econds at 54°C, and 20 seconds at 72°C and a ﬁnal
ycle of 4 minutes at 72°C.
ESULTS
A common polymorphism in hypervariable region
of the DP beta-chain abrogates an alloreactive
CE. We have previously shown that alloreactive T
ells obtained from a patient during the time of acute
SC allograft rejection recognized an alloreactive
CE encoded by DPB1*0901 and shared by a subset
f 5 other DPB1 alleles [13]. Among the DPB1 alleles
ot encoding the TCE, DPB1*4601 was the closest in
equence to DPB1*0901 because the polypeptides en-
oded by these 2 alleles differ only by 2 stretches of aa
n hypervariable regions A and E/F [28] (Figure 1). In
articular, DPB1*0901 encodes the sequence VHQL
n aa 8-11 of region A and V/DEAV in aa 76/84-87 of
egions E/F, whereas DPB1*4601 encodes LFQG and
/GGPM, respectively, in these positions. To deter-
ine the relative functional importance of these 2
egions for formation of the TCE, we constructed 2
ite-directed mutants of DPB1*0901, designated
PB1*09M/GGPM and DPB1*09LF, respectively, in
hich the 643 3= nucleotides of DPB1*0901 and
able 1. Primers and speciﬁcity of EST for DPB1
EST-AD
roduct length 214
orward primer
Sequence ccgcagagaattacgtgc
Region† A
Specificity‡ 9-11 HQL
everse primer
Sequence tccggcactgcccgctc
Region† D
Specificity‡ 69 E
lleles amplified§ 0901¶, 1001¶, 1602††, 1701¶,
3001††, 5401††, 5501††,
5801††, 8601#‡‡
. A. indicates not applicable.
Generic ampliﬁcation of all DRB alleles as reported [26].
Hypervariable region of the DP-beta chain [28,39,40] involved in
Polymorphic aa encoded by codons at the 3= end of the primer, m
DPB1* for columns EST-AD and EST-CE; DRB for column Co
DPB1* alleles tested for ampliﬁcation. Alleles lacking this callout
of the nucleotide sequence homology.
DPB1* alleles belonging to epitope group 1 (Table 2).
DPB1* alleles belonging to epitope group 2 (Table 2).
*DPB1* alleles belonging to epitope group 3 (Table 2).
†DPB1* alleles that could not be classiﬁed into any of the three e
‡DPB1*8601 was tested using the mutant allele DPB1*0901M/GPB1*4601 were shufﬂed (Figure 1). DPB1*09M/ DGPM is identical in sequence to the naturally oc-
urring DPB1*8601 allele [23,24], and is referred to
rom here on as DPB1*8601.
Recognition of the antigens encoded by the 2
utant alleles was tested by IFN- release assays
sing the same 2 alloreactive T cell clones, 501 and
38, that had been used to characterize the TCE in
igure 2. Reactivity of alloreactive T cell clones with site-directed
utants of DPB1*0901. Two alloreactive T cell clones with nom-
nal speciﬁcity for DPB1*0901, clone 501 (A) and clone 538 (B),
ere used as responders in a standard INF- release assay. The
timulator cells were HSR-DAV BLCL (DPB1*0201, *0401) before
untransduced) or after retroviral vector-mediated transfer of
EST-CE ControlR
92 276
ggcctgatgaggac cgtgtccccacagcacgtt
N. A.
7 DED 5-7 PRF
agttgtgtctgcatac ccgctgcactgtgaagct
N. A.
88-90 SFT
#, 0502#, 0901¶, 1401#,
02††, 2901††, 3501††, 4401††,
01††, 5701**, 6101N††, 7001††,
01††, 7801††, 8801††, 9201††
All
r speciﬁcity.
g primer speciﬁcity.
were not tested but can be predicted to be ampliﬁed on the basis
groups (Table 2).
which is identical in sequence to DPB1*8601 (see text).gggc
C
55-5
tcgt
E
76 V
0301
14
50
76
prime
ediatin
ntrol.
symbol
pitopePB1*0901, DPB1*4601, DPB1*8601, or DPB1*09LF.
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Epitope-Specific Matching for HLA-DPB1 1035he original study [13] (Figure 2). Both clones failed to
ecognize the patient’s BLCL, HSR-DAV, transduced
ith mutant DPB1*09LF. In contrast, the same
LCL transduced with DPB1*8601 was efﬁciently
ysed by clone 538 but not by clone 501 (Figure 2).
imilar data were obtained in a standard chromium
elease cytotoxicity assay (data not shown). Taken
ogether, our ﬁndings demonstrate that the presence
f aa LFQG in positions 8-11 in the hypervariable
egion A of the DP beta-chain abrogates the alloreac-
ive TCE, even if all the other aa of the polypeptide
re identical to the nominal antigen DPB1*0901. In
ontrast, the presence of aa V/DEAV in positions
6/84-87 modiﬁes the TCE but does not abrogate it.
CE Distribution among DPB1 Alleles
According to their pattern of recognition by 2
rototypes of alloreactive T cell clones, 501 and 538
13], we have previously shown that DPB1 alleles
an be clustered into 3 epitope groups, determining
he distribution of the alloreactive TCE. Alleles
PB1*0901, *1001, and *1701, encoding Ags rec-
gnized by both clones, were classiﬁed into epitope
roup 1. Epitope group 2 comprises alleles DPB1*
301, *1401, and *4501, encoding Ags recognized by
lone 501 but not 538. In addition, DPB1*0502,
hose exon 2 sequence encoding the peptide antigen
inding groove is identical to that of DPB1*0301 [24],
as also recognized by clone 501 but not 538 (data not
hown), concordant with its classiﬁcation into epitope
roup 2 (Table 2). On the basis of recognition by
lone 538 but not 501 (Figure 2), also DPB1*8601 can
e classiﬁed into epitope group 2 (Table 2). Interest-
ngly, of the antigens from epitope group 2, DP86 was
able 2. Classiﬁcation of DPB1 Alleles into Epitope Groups
Epitope
Group† D
0901, 1001, 1701
0301, 0502, 1401, 4501
8601¶
0101, 0201, 0202, 0401, 0402, 0501, 0601,
§ 0102, 0203, 0302, 0403, 0602, 0801, 0802,
3101, 3201, 3301, 3401, 3801, 3901, 4001
5901, 6001, 6201, 6301, 6501, 6801, 7101
8301, 8401, 9401, 9501, 9601, 9701, 9901
ot classified 0902, 1102, 1302, 1402, 1602, 1702, 1801,
3601, 3701, 4401, 5001, 5201, 5401, 5501
6901, 7001, 7401, 7601, 7801, 7901, 8501
9801
hown are all 114 DPB1 alleles encoding distinct polypeptides kno
. D. indicates not determined.
Epitope groups 1, 2, and 3 identiﬁed on the basis of recognition
Presence () or absence () of crossrecognition by alloreactive T
DPB1* alleles assigned to epitope group 3 on the basis of the pre
DPB1* alleles not assigned to any of the three epitope groups bec
aa LFQG in positions 8-11 of the DP beta-chain.
DPB1*8601 was tested using the mutant allele DPB1*09M/GGPM, whihe only 1 to be recognized by clone 538 but not 501
nd not vice versa, suggesting that the conformational
pitope present on DP86 is different from that present
n the other 3 Ags. However, with regard to their
elative immunogenicity, all alleles from group 2 were
ecognized by 1 of our T cell clones but not by the
ther. Fifteen alleles encoding antigens not recog-
ized by either of the 2 clones were classiﬁed into
pitope group 3 (Table 2). In addition, as described
bove, the LFQG mutation in aa positions 8-11 of
PB1*0901 abrogates recognition by both T cell
lones (Figure 2), demonstrating that all DPB1 al-
eles encoding this polymorphism in hypervariable
egion A can be classiﬁed into epitope group 3.
egion A is a tetramorphic zone with 58 of 114
PB1 alleles encoding distinct polypeptides de-
cribed to date carrying the sequence 8-11 LFQG
24], and hence belonging to epitope group 3 (Table 2).
Overall, based on functional data and sequence
nalysis of DPB1 alleles, we were able to classify 72
f 114 (63%) DPB1 alleles encoding distinct
olypeptides described to date into 1 of the 3
pitope groups, whereas 42 alleles could not be
lassiﬁed (Table 2).
robability of UD-Recipient Matching or Disparity
or the Alloreactive TCE at DPB1
The 4 main ethnic groups represented in the
orldwide UD registries are Caucasians, Asians, His-
anics, and Africans [4]. Allelic polymorphism at the
PB1 locus has been most comprehensively studied in
aucasians from different populations including
orthern European CEPH families [29], Swiss [30],
nd Germans [31], demonstrating similar allelic DPB1
T Cell Reactivity‡
501 538
 
 
 
301, 1501, 1601, 1901, 2001, 2301, 4601  
502, 1802, 1902, 2201, 2401, 2801,
, 4701, 4801, 4901, 5101, 5301, 5701,
, 7301, 7501, 7701, 8001, 8101, 8201,
N.D. N.D.
501, 2601, 2701, 2901, 3001, 3501,
, 5801, 6101N, 6401N, 6601, 6701,
, 8801, 8901, 9001, 9101, 9201, 9301,
N.D. N.D.
date.
eactive T cells with nominal speciﬁcity for DPB1*0901 [13].
ith nominal speciﬁcity for DPB1*0901.
f aa LFQG in positions 8-11 of the DP-beta chain (see text).
ey were not studied for T cell recognition and do not encode thePB1*
1101, 1
1002, 1
, 4101
, 7201
2101, 2
, 5601
, 8701
wn to
by allor
cells w
sence o
ause thch is identical in sequence to DPB1*8601 (see text).
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E. Zino et al.1036istributions in Caucasians from different countries.
hese frequencies, representatively shown for North-
rn European CEPH families, were in good agree-
ent with those derived in this study from DPB1
llelic typing of 216 unrelated healthy Italian individ-
als (Table 3). In the other 3 ethnic groups, conﬁdent
ata on DPB1 allelic polymorphism obtained on at
east 150 different alleles have been reported by Be-
ovich and colleagues for Asians from Japan, Hispan-
cs from Zapotec, and Africans from Cameroon and
able 3. DPB1 Allelic Frequencies in Different Ethnic Groups
DPB1*
Caucasian
Italy†
N  224
CEPH‡
N  247
lassified
Group 1§
0901 0.0231 0.012
1001 0.0324 0.004
1701 0.0208 0.024
Total 0.0763 0.040
Group 2§
0301 0.1088 0.126
1401 0.0463 0.016
Total 0.1551 0.142
Group 3§
0101 0.0278 0.036
0201 0.1968 0.109
0202 0.0046 0.012
0401 0.3310 0.409
0402 0.1111 0.130
0501 0.0162 0.032
0601 0.0046 0.024
1101 0.0255 0.024
1301 0.0278 0.012
1501 0.0023 0.016
1601 0.0023 0.004
1901 0.0046 0.004
2001 0.0046 0.004
4001 — —
4901 — —
6001 — —
6201 — —
Total 0.7638 0.816
otal 0.9952 0.998
ot classified¶
1801 — —
2701 — —
2901 — —
3001 — —
3501 — —
3901 — —
6101N — —
otal — —
indicates the number of alleles analyzed except for Caucasian CE
are only those alleles reported in at least one of the ethnic grou
Allelic frequencies reported in this study. Four decimal places are
these frequency data.
Allelic frequencies reported by Begovich and colleagues [32].
Epitope groups 1, 2, and 3 classiﬁed as reported in Table 2.
A proportion of alleles typed as DPB1*0301 could actually be DP
DPB1 alleles not assigned to any of the three epitope groups (Table 2).he Gambia [32]. Interestingly, in Caucasians, Asians,
nd Hispanics, only 23 of 114 DPB1 alleles encoding
istinct polypeptides described to date were reported
Table 3). For all of these 23 alleles, the presence or
bsence of the alloreactive TCE has been determined
n the present study, with 3, 3, and 17 alleles belong-
ng to epitope groups 1, 2, and 3, respectively (Table
). In contrast, Africans from Cameroon and The
ambia showed a stronger degree of DPB1 hetero-
eneity, both when compared with the other 3 ethnic
Hispanic African
2
Zapotec‡
N  170
Cameroon‡
N  344
The
Gambia‡
N  292
— — —
— — 0.010
— 0.035 0.270
— 0.035 0.280
0.012 0.032 0.038
0.018 0.003 0.007
0.030 0.035 0.045
— 0.212 0.322
0.035 0.125 0.137
— 0.009 —
0.135 0.110 0.010
0.753 0.233 0.065
0.006 — —
— — —
0.023 0.009 —
— 0.044 0.099
— — 0.007
— — —
— 0.006 —
— — —
— 0.014 0.017
— 0.014 —
— 0.026 —
— 0.006 —
0.952 0.808 0.657
0.982 0.878 0.982
— 0.102 —
— — 0.007
— 0.009 —
— — 0.003
— — 0.003
— — 0.003
— 0.003 —
— 0.114 0.016
ilies, where N indicates the number of distinct haplotypes. Listed
he present study or by Begovich and colleagues [32].
o ensure accuracy for the probability calculations performed using
2 [41]. Both alleles belong to epitope group 2 (Table 2).Asian
Japan‡
N  17
0.110
—
0.006
0.116
0.017
0.012
0.029
—
0.227
0.035
0.041
0.076
0.442
0.012
—
0.017
—
—
0.006
—
—
—
—
—
0.856
1.001
—
—
—
—
—
—
—
—
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Epitope-Specific Matching for HLA-DPB1 1037roups, and when compared between each other (Ta-
le 3). In particular, 3 and 4 alleles that could not be
lassiﬁed into any of the 3 epitope groups (Table 2)
ere reported in Africans from Cameroon and The
ambia, respectively, and these alleles were different
or the 2 populations (Table 3). Overall, only 30 dif-
erent DPB1 alleles have been reported in the 4 ethnic
roups representative of the worldwide UD registries
Table 3).
On the basis of these data, we have calculated the
robability for a patient from each of the 4 ethnic
roups to ﬁnd a UD matched or disparate for the
lloreactive TCE at DPB1, as described in Materials
nd Methods. In particular, TCE matching is present
hen the patient does not carry a DPB1 allele belong-
ng to a higher immunogenicity group compared to
he donor, or vice versa [13]. In this case, the pair
ould be DPB1 matched at the allelic level or DPB1
llele-level mismatched but TCE matched. In con-
rast, TCE disparity is present when the patient car-
ies at least 1 allele belonging to a higher immunoge-
icity group compared to the donor (the GVH
irection), or vice versa (the HVG direction) [13]. On
he basis of DPB1 allelic frequencies in Italy (Table 3),
D selected for an Italian patient have a 43% prob-
bility to be DPB1 TCE matched, whereas they have
28% probability to be DPB1 TCE disparate in the
VH or HVG direction (Table 4). These ﬁgures vary
nly slightly in Caucasians from Northern European
EPH families as well as in Japanese Asians and
fricans from The Gambia (Table 4). In contrast, UD
elected for a Zapotec Hispanic patient have a higher
robability to be DPB1 TCE matched (82%), and an
ccordingly lower probability to be DPB1 TCE dis-
arate in the GVH or HVG direction (5%; Table 4).
able 4. Probability of UD-Recipient DPB1 TCE Matching or
isparity in Different Ethnic Groups
M† GVH‡ HVG‡ M  GVH Total
aucasian§
Italy 0.43 0.28 0.28 0.71 0.99
CEPH 0.51 0.24 0.24 0.75 0.99
sian§
Japan 0.59 0.21 0.21 0.80 1.01
ispanic§
Zapotec 0.82 0.05 0.05 0.87 0.92
frican§
Cameroon 0.43 0.08 0.08 0.51 0.59
The Gambia 0.41 0.26 0.26 0.67 0.93
indicates matched; GVH, graft-versus-host; HVG,
host-versus-graft.
Probability for a patient of ﬁnding a UD from the same ethnic
group matched for the alloreactive TCE of DPB1.
Probability for a patient of ﬁnding a UD from the same ethnic
group disparate in GVH or HVG direction for the alloreactive
TCE of DPB1.
Probabilities were calculated on the basis of DPB1 allelic frequen-
Ccies reported in Table 3.his is because of the virtual absence of DPB1 alleles
rom epitope group 1 reported in Zapotec Hispanics
Table 3). In line with these observations, a recent
tudy of 44 individuals from the Mexican Tarahumara
merindians showed limited DPB1 variability with
nly 5 different alleles reported, all of which belonged
o epitope group 3 [33]. Additional studies of DPB1
llelic polymorphism in Hispanic populations are war-
anted to determine if the observed low frequency of
PB1 alleles from epitope group 1 and 2 represent a
eneral feature of Hispanic individuals.
Africans from Cameroon were difﬁcult to analyze
ecause of the relative high frequency (10.2%) of
PB1*1801 in this population, an allele that could not
e classiﬁed into any of the 3 DPB1 epitope groups
ccording to the established criteria (Table 3). Con-
equently, 43% of pairs from this population are pre-
icted not to be classiﬁable with regard to DPB1 TCE
atching or disparity (Table 4). In the remaining
airs, predicted TCE matching prevailed over TCE
isparity (43% matched versus 8% disparate GVH
nd 8% disparate HVG).
ST of DPB1 Alleles
To utilize the DPB1 algorithm to increase the
fﬁcacy of UD searches, a simple, fast, and low-cost
ssay for DPB1 matching is needed. Because of the
ature of DPB1 polymorphism generated mainly by
nterallelic nucleotide shufﬂing, high-resolution
-digit allele level DPB1 typing is difﬁcult to achieve
y SSOP, and requires a large number (usually 	40)
f different SSP reactions [25,27], accounting for the
igh time and cost intensity of this analysis. To cir-
umvent this problem, we have developed a protocol
or targeted detection of DPB1 alleles carrying the
lloreactive TCE, by EST with 2 epitope-speciﬁc
CR reactions, EST-AD and EST-CE, as described
n Materials and Methods (Table1). All 6 alleles from
pitope groups 1 and 2 (DPB1*0901, *1001, *1701,
0301, *0502, and *1401) reported in the 4 ethnic
roups representative of the worldwide UD registries
Table 3) were ampliﬁed by at least 1 of the 2 PCR
eactions, whereas none of the 17 alleles from epitope
roup 3 reported in these populations were ampliﬁed
Table 3, Figure 3A). When HSC donor-recipient
airs were matched by EST for these 23 DPB1 alleles,
ll possible combinations of results could be univo-
ally assigned to TCE identity or disparity in HVG or
VH direction (Figure 3B). When the 7 additional
lleles not classiﬁed so far into any of the 3 epitope
roups but reported in 2 Africans populations were
lso considered (Table 3), a positive or negative result
n either of the 2 PCR reactions accounted for by 1 of
hese alleles could be predicted to occur in 1.2% and
0.2% of the cases, respectively, in Africans from
ameroon and in 0.6% and 1% of the cases, respec-
t
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E. Zino et al.1038ively, in Africans from The Gambia (Table 3 and
igure 3A). EST was validated by analysis of 15 DPB1
yped reference cell lines as well as 112 unrelated
talian individuals comparatively subjected to conven-
ional intermediate resolution DPB1 SSOP typing in
ouble blind analysis, with 100% concordant results.
ISCUSSION
In this study, we demonstrate that UD-recipient
isparity in the HVG direction for a clinically relevant
lloreactive DPB1 TCE deﬁned previously by us [13],
an be predicted to be present in about 25% of unre-
ated HSC transplants when DPB1 is not included
nto the matching criteria (Table 4). These data are in
ine with our previous observations in 2 cohorts of
atients who underwent unrelated transplantation for
ncohematologic diseases [13] or beta-thalassemia
19]. We suggest that, in certain groups of patients
ncluding those enrolled in current well-standardized
ransplant protocols for beta-thalassemia, the clinical
igure 3. Interpretation of EST for DPB1. A, Presence () or
bsence () of ampliﬁcation by PCR primers in reaction EST-AD
r EST-CE, for DPB1 alleles listed in Table 3. “All” refers to the
7 DPB1 alleles classiﬁed into epitope group 3 listed in Table 3.
, HSC donor-recipient DPB1 matching by EST. Only those
lleles classiﬁed into epitope groups 1-3 and listed in Table 3 are
onsidered for interpretation. Shown are all possible combinations
f results with EST-AD (before the slash) or EST-CE (after the
lash) in the recipient (horizontal axis) or in the donor (vertical axis).
very combination is univocally associated with disparity for the
lloreactive TCE in GVH (light gray) or HVG (dark gray) direc-
ion, or with matching for the TCE (permissive mismatch or DPB1
dentity; PI, white).uccess rate of transplantation could be improved by melecting a UD not presenting such disparities, avail-
ble with a predicted probability of 75% (Table 4),
ompared to not considering DPB1 matching at all.
It should be noted that we have demonstrated an
dverse clinical effect associated with TCE disparities
n the HVG direction, in terms of graft rejection in
eta-thalassemia patients and aGVHD and TRM in
ncohematologic patients, whereas the effect of TCE
isparities in the GVH direction was more controver-
ial. Indeed, GVH disparities did not have a signiﬁcant
mpact on the incidence on aGVHD and thalassemia-
ree survival in beta-thalassemic patients [22]. In con-
rast, they were associated with TRM and aGVHD,
ut also with a slightly though not signiﬁcantly re-
uced risk of relapse in our study on oncohematologic
atients [13]. Interestingly, in a recent report from the
ritain donor registries, allelic DPB1 disparities were
hown to be associated with a lower risk of leukemia
elapse [34], suggesting that HLA-DP Ags can be
argets of graft-versus-leukemia (GVL). Based on the
urrently available data, we feel that avoidance of
PB1 disparities in HVG direction for our TCE
ight improve the clinical success of UD-SCT, com-
ared to not considering DPB1 matching at all,
hereas additional data are required to assess the
linical relevance of DPB1 TCE disparities in GVH
irection. In line with this notion, avoidance of DPB1
CE disparities in HVG direction has by now been
ncluded into the selection criteria of UD for beta-
halassemic patients, and conditioning regimen for
hese patients is modiﬁed when no UD without a
PB1 TCE disparity in HVG direction can be iden-
iﬁed (F. Locatelli and G. La Nasa, personal commu-
ication). It can be envisaged that EST could replace
onventional allele-level DPB1 typing in UD searches
or beta-thalassemic patients in the future. This would
epresent an innovative strategy for UD-recipient
atching associated with negligible investment of
ime and economical resources. It is important to note
hat our previous studies have identiﬁed to date only
linical relevant TCE disparity at the DPB1 locus, but
hat theoretically additional DPB1 TCE important
or the clinical outcome of UD HSCT might be char-
cterized in the future. Concordantly, although
atching for the alloreactive TCE identiﬁed by us
ould provide a clinical advantage over the current
ractice of not matching for DPB1 allele at all, it
annot be excluded that matching for additional TCE
ight prove relevant in the future.
EST might be extendable to other HLA loci once
dditional alloreactive TCE relevant for the clinical
utcome of transplantation will be identiﬁed. The
hallenge of such a strategy will rely not only on the
dentiﬁcation of the relevant TCE, but most impor-
antly on careful assessment of those patient groups
nd transplant conditions in which epitope disparities
ake a signiﬁcant difference for outcome. Indeed, the
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Epitope-Specific Matching for HLA-DPB1 1039linical relevance of our DPB1 TCE in oncohemato-
ogic patients, suggested by our previous results [13],
as yet to be conﬁrmed by detailed clinical studies of
ell-selected homogenous patient cohorts. The low-
ost and fast EST approach described in the present
tudy will considerably improve the feasibility of
arge-scale retrospective studies aimed at deﬁning the
linical relevance of UD-recipient TCE DPB1 dispar-
ties in correlation with different clinical variables in
SC transplantation, as well as in other transplant
ettings such as solid organ transplantation.
In the present study, site-directed mutagenesis
ave shown that the alloreactive DPB1 TCE is abro-
ated by a common polymorphism, LFQG, in aa
ositions 8-11, in hypervariable region A of the DP
eta-chain (Figure 2). This polymorphism is shared by
8 of the 114 DPB1 alleles, encoding different
olypeptides, described to date [24]. Although the
olecular basis for the dramatic effect of these aa on
he TCE is yet elusive, it is likely that it is at least
artly related to the aa sequence and/or the confor-
ation of the peptides accommodated in the antigen
inding groove. In line with this notion, it has been
hown that the peptide motif of HLA-DP2 and DP9,
prototypes of Ags with or without LFQG in aa
ositions 8-11, are profoundly different [35-37]. Ab-
ogation of the TCE by this polymorphism has been
f great practical help in classifying 72 different DPB1
lleles into epitope groups (Table 2), including all 23
lleles reported in 3 of the 4 ethnic group represen-
atives of the worldwide UD registries (Table 3). On
he basis of this knowledge, we have also been able to
redict the probability for patients of the 4 main
thnic groups to ﬁnd a UD with or without a nonper-
issive DPB1 disparity (Table 4). These data are
ased on a number of large population studies in
aucasians (Table 3) [29-31], whereas they are to be
onsidered with caution for the other 3 ethnic groups,
ecause of the limited number of data available on
PB1 allelic polymorphism in these populations. In-
erestingly, the prediction varied substantially be-
ween Africans from The Gambia and Cameroon
Table 4), mainly because of to the relative prevalence
f DPB1*1801 in the latter population, an allele that
as so far not been classiﬁed into any of the 3 epitope
roups (Table 2). These ﬁndings suggest the presence
f considerable differences in DPB1 allelic distribu-
ion within different African populations, a situation
hat could potentially also apply to Hispanics and
ifferent Asian populations, whereas such differences
re found to a much lower degree in Caucasians
29-31] (Table 3). In line with these observations,
rom a phylogenetic point of view, DPB1 alleles can
e clustered into an Asian/European and an African/
ispanic group, and within the latter, Gambians are
eparate from other African populations such as Afri-
ans from Uganda or Gabon [38]. Large-scale studiesf DPB1 polymorphism in different Asian, Hispanic,
nd African populations are warranted to reliably pre-
ict the probability for patients from these ethnic
roups to ﬁnd an UD matched or disparate for the
PB1 TCE.
In conclusion, the EST approach presented in this
tudy is the ﬁrst protocol of targeted, epitope-speciﬁc
PB1 UD-recipient matching in unrelated HSC
earches, which will prove useful for deﬁning the rel-
vance of DPB1 TCE disparities in different trans-
lant conditions by retrospective clinical studies. In
elected groups of transplants such as those performed
or beta-thalassemia, epitope- rather than allele-spe-
iﬁc UD-recipient DPB1 matching by EST could
mprove clinical outcome without signiﬁcantly limit-
ng the number of functionally matched UD. Epitope-
peciﬁc typing, might represent a challenging alterna-
ive to conventional tissue typing, which, if applied to
ther HLA loci, could fundamentally change current
pproaches to UD searches.
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